Renin-angiotensin system blockers and COVID-19

Emmanuelle Vidal-Petiot; Nathalie Gault

doi:10.1186/s12916-021-02012-6

Renin-angiotensin system blockers and COVID-19

BMC Med. 2021 Jun 4;19(1):136. doi: 10.1186/s12916-021-02012-6.

Authors

Emmanuelle Vidal-Petiot^{1

2}, Nathalie Gault^{3

4}

Affiliations

¹ Assistance Publique-Hôpitaux de Paris, Physiology department, Bichat-Claude Bernard University Hospital, 46 rue Henri Huchard, Paris, France. emmanuelle.vidal-petiot@aphp.fr.
² Université de Paris, Inserm U1149, 75018, Paris, France. emmanuelle.vidal-petiot@aphp.fr.
³ INSERM CIC-EC 1425, hôpital Bichat Claude Bernard, 75018, Paris, France.
⁴ APHP.Nord, Département Epidémiologie Biostatistiques et Recherche Clinique, Hôpital Bichat, 75018, Paris, France.

No abstract available

Keywords: Angiotensin receptor blockers; Angiotensin-converting enzyme inhibitors; COVID-19; RAS blockers; Renin-angiotensin-aldosterone system; SARS-CoV-2.

Publication types

Letter
Comment

MeSH terms

Angiotensin Receptor Antagonists / adverse effects
COVID-19*
Enzyme Inhibitors
Hospitals
Humans
Renin-Angiotensin System*
Retrospective Studies
SARS-CoV-2

Substances

Angiotensin Receptor Antagonists
Enzyme Inhibitors